Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 15/20 | 0.39 |
| ▸ | FNTB | P49356 | 15/20 | 0.39 |
| ▸ | RORC | P51449 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | PGGT1B | P53609 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5781627 | 0.89 | FNTA (0.51) | FNTAFNTBPGGT1B | |
| SCHEMBL5781497 | 0.89 | FNTA (0.49) | FNTAFNTBRORC | |
| SCHEMBL5781104 | 0.76 | FNTA (0.51) | FNTAFNTBRORC | |
| SCHEMBL5655111 | 0.75 | FNTA (0.57) | FNTAFNTBKMT2APGGT1B | |
| Hydrochloric Acid SCHEMBL5658416 | 0.75 | FNTA (0.56) | FNTAFNTBKMT2APGGT1B | |
| SCHEMBL5781452 | 0.73 | FNTA (0.68) | FNTAFNTBRORC | |
| SCHEMBL5777051 | 0.73 | FNTA (0.68) | FNTAFNTBPGGT1B | |
| Water SCHEMBL5778871 | 0.72 | FNTA (0.67) | FNTAFNTBRORC | |
| SCHEMBL5656136 | 0.70 | FNTA (0.48) | FNTAFNTBMAPTKMT2APGGT1B | |
| SCHEMBL5783981 | 0.69 | FNTA (0.68) | FNTAFNTBRORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7053105-B2 | Farnesyl transferase inhibiting quinoline and quinazoline derivatives as farnesyl transferase inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-05-30 | — | — | US | disclosed |
| EP-1322635-B1 | FARNESYL TRANSFERASE INHIBITING QUINOLINE AND QUINAZOLINE DERIVATIVES AS FARNESYL TRANSFERASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2006-03-22 | — | — | EP | disclosed |
| US-20030203904-A1 | Farnesyl transferase inhibiting quinoline and quinazoline derivatives as farnesyl transferase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-10-30 | — | — | US | disclosed |
| EP-1322635-A1 | FARNESYL TRANSFERASE INHIBITING QUINOLINE AND QUINAZOLINE DERIVATIVES AS FARNESYL TRANSFERASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-07-02 | — | — | EP | disclosed |
| WO-2002024682-A1 | FARNESYL TRANSFERASE INHIBITING QUINOLINE AND QUINAZOLINE DERIVATIVES AS FARNESYL TRANSFERASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2002-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030203904-A1 | Farnesyl transferase inhibiting quinoline and quinazoline derivatives as farnesyl transferase inhibitors | FNTA, FNTB, RABGGTB | FNTA 1/4885FNTB 2/4885RORC 886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.